| | | | | | | | | | |
|
|
|
|
| Dockets Entered
On December 7, 2007
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1978N-0038
|
| Sunscreen Drug Products
|
|
|
|
|
| 2003N-0573
|
| Draft Animal Cloning Risk Assessment
|
|
|
|
|
| 2005P-0450
|
| Revoke the GRAS Status of Salt, Set Ceilings on the Amount of Sodium in Processed Foods, Require a Health Warning on Packaged Salt, and Reduce the Daily Value for Sodium
|
|
|
|
|
| 2006F-0409
|
| Safe Use of Cetylpyridinium Chloride as an Antimicrobial Agent in a Pre-chiller or Post-chiller Solution for Application to Raw Poultry Carcasses (FAP 6A4767)
|
|
|
|
|
| 2006N-0061
|
| Charging for Investigational Drugs
|
|
|
|
|
| 2006N-0221
|
| Requirements for Human Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use
|
|
|
|
|
| 2006N-0454
|
| Use of Ozone-Depleting Substances; Removal of Essential-Use Designations
|
|
|
|
|
| 2006P-0394
|
| Revise the labeling requirements for eggs sold in the United States
|
|
|
|
|
| 2007D-0364
|
| Impact-Resistant Lenses: Questions and Answers Guidance
|
|
|
|
|
| 2007M-0467
|
| P060031 - Bio-Rad MONOLISA Anti-HBc EIA
|
|
|
|
|
| 2007N-0356
|
| BEHIND THE COUNTER AVAILABILITY OF CERTAIN DRUGS; Public Meeting
|
|
|
|
|
| 2007P-0085
|
| Adopt Regulations of General Applicability to all Food Standards that would Permit Deviations from the Requirements of the Individual Food Standards of Identity
|
|
|
|
|
| 2007P-0400
|
| Formally ban unnaturally synthesized fluoride compounds sold for consumption through oral ingestion
|
|
|
|
|
| 2007P-0457
|
| Mandatory Use of Non-Animal Methods in the Development and Approval of Drugs and Devices
|
|
|
|
|
| 2007P-0473
|
| To seek the creation of a new Food and Drug Administration policy to achieve expanded anh accelerated development and production of pre-pandemic and pandemic vaccine
|
|
| |
|
| 1978N-0038
|
| Sunscreen Drug Products
|
|
|
|
|
| C 710
|
| State of Virginia
|
| Vol #:
|
| 176
|
|
|
|
|
| 2003N-0573
|
| Draft Animal Cloning Risk Assessment
|
|
|
|
|
| C 4069
|
| Unknown
|
| Vol #:
|
| 238
|
|
|
|
|
| 2005P-0450
|
| Revoke the GRAS Status of Salt, Set Ceilings on the Amount of Sodium in Processed Foods, Require a Health Warning on Packaged Salt, and Reduce the Daily Value for Sodium
|
|
|
|
|
| EC 31
|
| Purity Foods
|
| Vol #:
|
| 1
|
|
|
|
|
| EC 32
|
| Ms. Laurie Lamberth
|
| Vol #:
|
| 1
|
|
|
|
|
| EC 33
|
| none
|
| Vol #:
|
| 1
|
|
|
|
|
| EC 34
|
| Mrs. Monna Watchinski
|
| Vol #:
|
| 1
|
|
|
|
|
| EC 35
|
| the ohio state university
|
| Vol #:
|
| 1
|
|
| |
|
| 2006F-0409
|
| Safe Use of Cetylpyridinium Chloride as an Antimicrobial Agent in a Pre-chiller or Post-chiller Solution for Application to Raw Poultry Carcasses (FAP 6A4767)
|
|
|
|
|
| EC 4
|
| Dr. Robert Bissell
|
| Vol #:
|
| 1
|
|
|
|
|
| EC 5
|
| Mr. Richard Campora
|
| Vol #:
|
| 1
|
|
|
|
|
| EC 6
|
| Dr. norman kaplan
|
| Vol #:
|
| 1
|
|
|
|
|
| EC 7
|
| Nova Southeastern University
|
| Vol #:
|
| 1
|
|
|
|
|
| EC 8
|
| univ of cincinnati med ctr
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006N-0061
|
| Charging for Investigational Drugs
|
|
|
|
|
| C 15
|
| UnitedHealthcare
|
| Vol #:
|
| 2
|
|
| | | | | | | | |
|
| |
|
| 2006N-0221
|
| Requirements for Human Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use
|
|
|
|
|
| C 2
|
| New York Blood Center
|
| Vol #:
|
| 1
|
|
|
|
|
| EC 6
|
| America's Blood Centers
|
| Vol #:
|
| 1
|
|
| |
|
| 2006N-0454
|
| Use of Ozone-Depleting Substances; Removal of Essential-Use Designations
|
|
|
|
|
| C 4261
|
| D. Gantz
|
| Vol #:
|
| 40
|
|
|
|
|
| C 4262
|
| R. W. Price
|
| Vol #:
|
| 40
|
|
|
|
|
| C 4263
|
| C. Vance
|
| Vol #:
|
| 40
|
|
|
|
|
| 2006P-0394
|
| Revise the labeling requirements for eggs sold in the United States
|
|
|
|
|
| C 495
|
| E. O' Hara
|
| Vol #:
|
| 14
|
|
|
|
|
| C 496
|
| R. I. Powell
|
| Vol #:
|
| 14
|
|
|
|
|
| C 497
|
| M. Evenson
|
| Vol #:
|
| 14
|
|
|
|
|
| 2007D-0364
|
| Impact-Resistant Lenses: Questions and Answers Guidance
|
|
|
|
|
| EC 3
|
| EYE2EYE, INC.
|
| Vol #:
|
| 1
|
|
|
|
|
| EC 4
|
| Gregory's Optical
|
| Vol #:
|
| 1
|
|
|
|
|
| EC 5
|
| Dr. Charles McBride
|
| Vol #:
|
| 1
|
|
|
|
|
| EC 6
|
| Mr. Matt Ford
|
| Vol #:
|
| 1
|
|
|
|
|
| EC 7
|
| OAA OPTICIAN
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007M-0467
|
| P060031 - Bio-Rad MONOLISA Anti-HBc EIA
|
|
|
|
|
| AAV 1
|
| Bio-Rad Laboratories
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007N-0356
|
| BEHIND THE COUNTER AVAILABILITY OF CERTAIN DRUGS; Public Meeting
|
|
|
|
|
| EC 122
|
| Mrs. Neela Desai
|
| Vol #:
|
| 2
|
|
|
|
|
| 2007P-0085
|
| Adopt Regulations of General Applicability to all Food Standards that would Permit Deviations from the Requirements of the Individual Food Standards of Identity
|
|
|
|
|
| C 360
|
| D. Dirst
|
| Vol #:
|
| 102
|
|
|
|
|
| 2007P-0400
|
| Formally ban unnaturally synthesized fluoride compounds sold for consumption through oral ingestion
|
|
|
|
|
| C 3
|
| Richard Sauerheber
|
| Vol #:
|
| 1
|
|
| |
|
| 2007P-0457
|
| Mandatory Use of Non-Animal Methods in the Development and Approval of Drugs and Devices
|
|
|
|
|
| EC 1
|
| Mr. Barry Cole
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007P-0473
|
| To seek the creation of a new Food and Drug Administration policy to achieve expanded anh accelerated development and production of pre-pandemic and pandemic vaccine
|
|
|
|
|
| ACK 1
|
| FDA/ DDM to William L. Driscoll
|
| Vol #:
|
| 1
|
|
|
|
|
| CP 1
|
| W. L. Driscoll
|
| Vol #:
|
| 1
|
|
